guanfacine and Incipient Schizophrenia studies

Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.

Research Excerpts

Excerpt	Relevance	Reference
"Twenty-eight participants with schizotypal personality disorder enrolled in an 8-week, randomized, double-blind, placebo-controlled trial of guanfacine plus cognitive remediation and social skills training (15 guanfacine, 13 placebo)."	9.30	Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder. ( Graff, F; Harvey, PD; Hazlett, EA; Koenigsberg, H; McClure, MM; New, AS; Perez-Rodriguez, M; Rosell, DR; Siever, LJ; Triebwasser, J, 2019)
"Twenty-eight participants with schizotypal personality disorder enrolled in an 8-week, randomized, double-blind, placebo-controlled trial of guanfacine plus cognitive remediation and social skills training (15 guanfacine, 13 placebo)."	5.30	Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder. ( Graff, F; Harvey, PD; Hazlett, EA; Koenigsberg, H; McClure, MM; New, AS; Perez-Rodriguez, M; Rosell, DR; Siever, LJ; Triebwasser, J, 2019)

Research

Studies (3)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Inferior Parietal Lobule

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
McClure, MM	2
Graff, F	1
Triebwasser, J	2
Perez-Rodriguez, M	1
Rosell, DR	1
Koenigsberg, H	1
Hazlett, EA	1
Siever, LJ	2
Harvey, PD	2
New, AS	1
McGurk, SR	1
Barch, DM	1
Romero, MJ	1
Minzenberg, MJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum[NCT02524899]	Phase 2	45 participants (Actual)	Interventional	2014-01-31	Completed
Pharmacology of Cognition in Schizotypal Personality Disorder: Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder[NCT00353379]	Phase 4	29 participants (Actual)	Interventional	1995-09-30	Terminated (stopped due to low enrollment)
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects[NCT01600885]		16 participants (Actual)	Interventional	2008-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"Scans will be analyzed for task-related prefrontal activation~Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline)" (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Middle Frontal Gyrus

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.17
Placebo	-0.094

Difference Score: Percent Signal Change in Regions of Interest (ketamine - saline) (NCT01600885)
Timeframe: Within 4 hours of dose administration, after up to 1.25 hours of ketamine infusion

Percent Change in Amelioration of Ketamine-related Task Activation as Measured by Functional Magnetic Resonance Imaging in Superior Frontal Gyrus

Intervention	percent change in saline signal (Mean)
Guanfacine	-0.1
Placebo	0.052